Related Experiment Video
Updated: Jun 18, 2025
12:55
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
21.4K
Lung Cancer Adoptive Cell Therapy: Inspiring TIL ACT Comes Center Stage.
Michael T Lotze1, Markus Maeurer2, Sergio A Quezada3
1University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, Pennsylvania.
Cancer Discovery
|August 2, 2024
Summary
Lifileucel, a cell therapy using tumor-infiltrating lymphocytes (TIL), showed a 21.4% objective response rate in advanced non-small cell lung cancer. This offers hope for new treatments beyond melanoma.
Area of Science:
- Oncology
- Immunotherapy
- Cell Therapy
Background:
- Lifileucel, a cell therapy derived from autologous tumor-infiltrating lymphocytes (TIL), has previously demonstrated efficacy in advanced melanoma, leading to FDA approval.
- Non-small cell lung cancer (NSCLC) remains a significant challenge, with limited treatment options for advanced stages.
Purpose of the Study:
- To evaluate the efficacy of lifileucel in patients with advanced non-small cell lung cancer.
- To assess the objective response rate (ORR) of lifileucel in this patient population.
Main Methods:
- A clinical study involving patients with advanced non-small cell lung cancer treated with lifileucel.
- Assessment of objective response rate as a primary endpoint.
Main Results:
- Schoenfeld and colleagues reported an objective response rate of 6/28 (21.4%) in patients with advanced non-small cell lung cancer receiving lifileucel.
- This represents a measurable response to the cell therapy in a new tumor histology.
Conclusions:
- The findings suggest that lifileucel holds promise for treating advanced non-small cell lung cancer.
- This study supports ongoing efforts to optimize tumor-infiltrating lymphocyte (TIL) therapy for various cancer types.
Related Concept Videos
01:27Tumor Immunotherapy
498
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
498
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:30Cancer Vaccines
347
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
347